These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38263653)

  • 1. Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study).
    van Nimwegen JF; Mossel E; van Zuiden GS; Wijnsma RF; Delli K; Stel AJ; van der Vegt B; Haacke EA; Olie L; Los LI; Verstappen GM; Pringle SA; Spijkervet FKL; Kroese FGM; Vissink A; Arends S; Bootsma H
    Lancet Rheumatol; 2020 Mar; 2(3):e153-e163. PubMed ID: 38263653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
    Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
    Fisher BA; Szanto A; Ng WF; Bombardieri M; Posch MG; Papas AS; Farag AM; Daikeler T; Bannert B; Kyburz D; Kivitz AJ; Carsons SE; Isenberg DA; Barone F; Bowman SJ; Espié P; Floch D; Dupuy C; Ren X; Faerber PM; Wright AM; Hockey HU; Rotte M; Milojevic J; Avrameas A; Valentin MA; Rush JS; Gergely P
    Lancet Rheumatol; 2020 Mar; 2(3):e142-e152. PubMed ID: 38263652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
    Fisher BA; Mariette X; Papas A; Grader-Beck T; Bootsma H; Ng WF; van Daele PLA; Finzel S; Noaiseh G; Elgueta S; Hermann J; McCoy SS; Akpek E; Bookman A; Sopala M; Montecchi-Palmer M; Luo WL; Scheurer C; Hueber W;
    Lancet; 2024 Aug; 404(10452):540-553. PubMed ID: 39096929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
    Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
    van der Heijden EHM; Blokland SLM; Hillen MR; Lopes APP; van Vliet-Moret FM; Rosenberg AJWP; Janssen NG; Welsing PMJ; Iannizzotto V; Tao W; Pandit A; Barone F; Kruize AA; Radstake TRDJ; van Roon JAG
    Lancet Rheumatol; 2020 May; 2(5):e260-e269. PubMed ID: 38273473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure.
    Arends S; de Wolff L; van Nimwegen JF; Verstappen GMPJ; Vehof J; Bombardieri M; Bowman SJ; Pontarini E; Baer AN; Nys M; Gottenberg JE; Felten R; Ray N; Vissink A; Kroese FGM; Bootsma H
    Lancet Rheumatol; 2021 Aug; 3(8):e553-e562. PubMed ID: 38287621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial.
    de Wolff L; van Nimwegen JF; Mossel E; van Zuiden GS; Stel AJ; Majoor KI; Olie L; Los LI; Vissink A; Spijkervet FKL; Verstappen GMPJ; Kroese FGM; Arends S; Bootsma H
    Semin Arthritis Rheum; 2022 Apr; 53():151955. PubMed ID: 35091325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.
    Chung L; Spino C; McLain R; Johnson SR; Denton CP; Molitor JA; Steen VD; Lafyatis R; Simms RW; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Sandorfi N; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Allanore Y; Matucci-Cerinic M; Whitfield ML; Distler O; Singer O; Young A; Nagaraja V; Fox DA; Furst DE; Khanna D
    Lancet Rheumatol; 2020 Dec; 2(12):e743-e753. PubMed ID: 34966900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
    Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
    Cope AP; Jasenecova M; Vasconcelos JC; Filer A; Raza K; Qureshi S; D'Agostino MA; McInnes IB; Isaacs JD; Pratt AG; Fisher BA; Buckley CD; Emery P; Ho P; Buch MH; Ciurtin C; van Schaardenburg D; Huizinga T; Toes R; Georgiou E; Kelly J; Murphy C; Prevost AT;
    Lancet; 2024 Mar; 403(10429):838-849. PubMed ID: 38364839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
    Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Sztajnbok F; Goldenstein-Schainberg C; Scheinberg M; Penades IC; Fischbach M; Orozco J; Hashkes PJ; Hom C; Jung L; Lepore L; Oliveira S; Wallace CA; Sigal LH; Block AJ; Covucci A; Martini A; Giannini EH; ;
    Lancet; 2008 Aug; 372(9636):383-91. PubMed ID: 18632147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
    Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM
    Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
    Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
    Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Traditional Chinese Medicine in Patients With Primary Sjogren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Chen HH; Lai JN; Yu MC; Chen CY; Hsieh YT; Hsu YF; Wei JC
    Front Med (Lausanne); 2021; 8():744194. PubMed ID: 34651000
    [No Abstract]   [Full Text] [Related]  

  • 17. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.
    Felten R; Devauchelle-Pensec V; Seror R; Duffau P; Saadoun D; Hachulla E; Pierre Yves H; Salliot C; Perdriger A; Morel J; Mékinian A; Vittecoq O; Berthelot JM; Dernis E; Le Guern V; Dieudé P; Larroche C; Richez C; Martin T; Zarnitsky C; Blaison G; Kieffer P; Maurier F; Dellal A; Rist S; Andres E; Contis A; Chatelus E; Sordet C; Sibilia J; Arnold C; Tawk MY; Aberkane O; Holterbach L; Cacoub P; Saraux A; Mariette X; Meyer N; Gottenberg JE
    Ann Rheum Dis; 2021 Mar; 80(3):329-338. PubMed ID: 33208345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
    Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
    Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.